PYRANTEL PAMOATE

N/A

Manufactured by REESE PHARMACEUTICAL CO.

83 FDA adverse event reports analyzed

Last updated: 2026-04-15

About PYRANTEL PAMOATE

PYRANTEL PAMOATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by REESE PHARMACEUTICAL CO.. The most commonly reported adverse reactions for PYRANTEL PAMOATE include ADVERSE EVENT, DRUG INEFFECTIVE, ENTEROBIASIS, HEADACHE, TREATMENT FAILURE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PYRANTEL PAMOATE.

Top Adverse Reactions

ADVERSE EVENT17 reports
DRUG INEFFECTIVE4 reports
ENTEROBIASIS4 reports
HEADACHE3 reports
TREATMENT FAILURE3 reports
HELMINTHIC INFECTION2 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION2 reports
ACCIDENT AT WORK1 reports
ACCIDENTAL OVERDOSE1 reports
ANAL FUNGAL INFECTION1 reports
ANXIETY1 reports
BLINDNESS1 reports
BRAIN NATRIURETIC PEPTIDE INCREASED1 reports
BRONCHITIS1 reports
CANDIDA INFECTION1 reports
CERVIX CANCER METASTATIC1 reports
CHROMATURIA1 reports
COLONOSCOPY1 reports
CONFUSIONAL STATE1 reports
CONJUNCTIVAL HYPERAEMIA1 reports
CONJUNCTIVITIS1 reports
DEATH1 reports
DEHYDRATION1 reports
DERMATITIS ATOPIC1 reports
DRUG INTERACTION1 reports
DYSPNOEA1 reports
DYSPNOEA EXERTIONAL1 reports
EYE INFECTION STAPHYLOCOCCAL1 reports
GAIT DISTURBANCE1 reports
HAEMOPTYSIS1 reports
HEART RATE INCREASED1 reports
HYPERTENSION1 reports
INCORRECT DOSE ADMINISTERED1 reports
LEIOMYOMA1 reports
LEUKOCYTOCLASTIC VASCULITIS1 reports
LIVER INJURY1 reports
NASOPHARYNGITIS1 reports
NAUSEA1 reports
NERVOUS SYSTEM DISORDER1 reports
OVERDOSE1 reports
PANIC REACTION1 reports
PRODUCT DOSE OMISSION ISSUE1 reports
PRODUCT USE IN UNAPPROVED INDICATION1 reports
PULMONARY OEDEMA1 reports
PULMONARY THROMBOSIS1 reports
RENAL IMPAIRMENT1 reports
RESPIRATORY DISTRESS1 reports
RHINORRHOEA1 reports
SUBCONJUNCTIVAL FIBROSIS1 reports
SYMBLEPHARON1 reports
THERAPEUTIC RESPONSE UNEXPECTED1 reports
TREATMENT NONCOMPLIANCE1 reports
URINARY TRACT INFECTION1 reports
VISION BLURRED1 reports
VULVOVAGINAL MYCOTIC INFECTION1 reports

Report Outcomes

Out of 46 classified reports for PYRANTEL PAMOATE:

Serious 30.4%Non-Serious 69.6%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female14 (56.0%)
Male9 (36.0%)
Unknown2 (8.0%)

Reports by Age

Age 52 reports
Age 512 reports
Age 21 reports
Age 61 reports
Age 121 reports
Age 221 reports
Age 271 reports
Age 331 reports
Age 361 reports
Age 421 reports
Age 431 reports
Age 471 reports
Age 561 reports
Age 591 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with PYRANTEL PAMOATE?

This profile reflects 83 FDA FAERS reports that mention PYRANTEL PAMOATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for PYRANTEL PAMOATE?

Frequently reported terms in FAERS include ADVERSE EVENT, DRUG INEFFECTIVE, ENTEROBIASIS, HEADACHE, TREATMENT FAILURE, HELMINTHIC INFECTION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures PYRANTEL PAMOATE?

Labeling and FAERS entries often list REESE PHARMACEUTICAL CO. in connection with PYRANTEL PAMOATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.